Assessment of Disease Burden in Hairy Cell Leukemia
NCT06781515 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2025-01-17
Summary
Drug-free, single-center, prospective observational pilot study in hairy Cell Leukemia patients
Conditions
- Hairy Cell Leukemia
Interventions
- OTHER
-
Peripheral and BM blood sample
Peripheral and BM blood samples will be analyzed with the ddPCR method
Sponsors & Collaborators
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
lead OTHER
Principal Investigators
-
Pier Luigi Zinzani, MD · IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-31
- Primary Completion
- 2025-11-30
- Completion
- 2025-11-30
Countries
- Italy
Study Locations
More Related Trials
-
Genotyping Analysis of Acute Lymphoblastic Leukemia
NCT00961285 ·Status: UNKNOWN
-
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
NCT01841723 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
NCT04621851 ·Status: COMPLETED
-
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
NCT02711852 ·Status: COMPLETED ·Phase: PHASE2
-
Identification of BCR::ABL1 Mutations by Digital PCR in CML
NCT07158294 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer
NCT05035615 ·Status: COMPLETED
-
Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01185886 ·Status: UNKNOWN
-
Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA)
NCT07060612 ·Status: ACTIVE_NOT_RECRUITING
-
Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2
NCT04070807 ·Status: UNKNOWN
-
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
NCT01761890 ·Status: UNKNOWN
-
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
NCT04150471 ·Status: UNKNOWN
-
Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL
NCT03123887 ·Status: COMPLETED
-
Treatment of Acute Myeloblastic Leukemia in Younger Patients
NCT00390715 ·Status: COMPLETED
-
LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION
NCT07313982 ·Status: RECRUITING
-
Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
NCT01251627 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation
NCT05611216 ·Status: COMPLETED
-
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
NCT05260528 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia
NCT02823132 ·Status: COMPLETED
-
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
NCT05619978 ·Status: COMPLETED
-
A Prognostic Tool for Early Stage CLL
NCT03436524 ·Status: COMPLETED
-
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
NCT04861779 ·Status: UNKNOWN ·Phase: PHASE1
-
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients
NCT01578213 ·Status: COMPLETED ·Phase: PHASE4
-
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
NCT02348957 ·Status: COMPLETED
-
Study on the Diagnosis and Management of CLL in Italy by GIMEMA
NCT04867915 ·Status: RECRUITING
-
Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization
NCT02975115 ·Status: UNKNOWN